C4 Therapeutics share price logo

C4 Therapeutics

NASDAQ: CCCC

Small Cap

$2.65

-0.12

(-4.50%)

Live

as on

C4 Therapeutics Stock Performance

as on October 15, 2026 at 4:09 am IST

  • Day's Low

    Day's High

    $2.64
    $2.79
    downward going graph

    0.38%

    Downside

    5.28%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.69
    $5.17
    downward going graph

    36.22%

    Downside

    95.09%

    Upside

    downward going graph

C4 Therapeutics share price movements today

Previous Close
$2.78
Open
$2.70
Volume
1.5M
Market Cap
$346.3M
Day's Low - High
$2.64 - $2.79
52 Week Low - High
$1.69 - $5.17

C4 Therapeutics Historical Returns

1 Month Return
-18.95 %
3 Month Return
-27.03 %
1 Year Return
+ 37.62 %
3 Year Return
+ 39.7 %
5 Year Return
-93.71 %

C4 Therapeutics Stock Fundamentals & Key Indicators

Check C4 Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$346.3M

EPS (TTM)

-1

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-3.06

Industry PE ratio

-6.42

PEG Ratio

-0.07

EBITDA

-99.7M

Revenue (TTM)

35.0M

Profit Margin

94.86%

Return On Equity TTM

-45.45%

C4 Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of C4 Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
C4 Therapeutics image
C4 Therapeutics
StrongBuy$346.3M-93.71%-3.0694.86%0.00%
Moderna image
Moderna
Neutral$85.3B-34.84%-28.20-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$128.5B166.75%29.4586.04%0.00%
Regeneron image
Regeneron
Buy$78.5B35.55%17.8384.86%0.49%

Stock Returns calculator for C4 Therapeutics Stock including INR - Dollar returns

The C4 Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

C4 Therapeutics investment value today

Current value as on today

₹1,40,583

Returns

₹40,583

(+40.58%)

Returns from C4 Therapeutics Stock

₹31,188 (+31.19%)

Dollar Impact

₹9,395 (+9.39%)

Analyst Recommendation on C4 Therapeutics Stock

Based on 4 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 4 analysts, 100% of analysts recommend a 'BUY' rating for C4 Therapeutics. Average target price of $12.86

C4 Therapeutics Share Price Target

Get share price movements and forecasts by analysts on C4 Therapeutics.

What analysts predicted

79.39%UPSIDE

Target Price

$12.86

Current Price

$2.65

Analyzed by

4 Analysts

High

$10

Target

$12.86

Low

$7

C4 Therapeutics target price $12.86, a slight upside of 79.39% compared to current price of $2.65. According to 4 analysts rating.

Indian Investors' Interest in C4 Therapeutics Stock

Search interest for C4 Therapeutics Stock has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-14% versus previous 30 day period

C4 Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
3
12
15
5
7
6
11
11
6
6
Gross Profit
3
9
13
3
7
6
11
11
4
6
Operating Income
-32
-21
-28
-37
-29
-28
-34
-23
-27
-26
EBITDA
-29
-17
-24
-33
-25
-25
-31
-19
-24
-23
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-28
-17
-24
-34
-26
-26
-32
-20
-25
-23
Income Tax Expense
-
-
-
0
-
-
-
0
-
-
Net Income
-28
-17
-24
-34
-26
-26
-32
-20
-25
-23
Net Profit Margin
100.00%
82.97%
86.62%
65.89%
100.00%
100.00%
100.00%
100.00%
70.72%
100.00%

C4 Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
19
21
33
45
31
20
35
35
Gross Profit
-9
21
-45
45
31
13
35
27
Operating Income
-16
-35
-60
-82
-129
-139
-119
-104
EBITDA
-15
-31
-58
-80
-124
-127
-103
-102
Interest Expense
-
-
1
2
2
1
-
-
Depreciation
1
1
1
1
1
1
1
1
Income Before Tax
-15
-33
-65
-83
-128
-131
-105
-104
Income Tax Expense
-
0
0
-
-
1
0
0
Net Income
-15
-34
-66
-83
-128
-132
-105
-104
Net Profit Margin
-47.66%
100.00%
-136.30%
100.00%
100.00%
62.72%
100.00%
77.81%

C4 Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-28
-17
-24
-34
-26
-26
-32
-20
-25
-23
Operating Cash Flow
-18
-4
-24
-17
-33
-12
-31
-22
-29
-1
Investing Cash Flow
-53
-11
0
13
29
38
4
-80
16
-14
Financing Cash Flow
34
0
10
0
0
-
7
118
0
33
Change in Cash
-36
-16
-13
-4
-4
26
-19
15
-13
17

C4 Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-15
-34
-66
-83
-128
-132
-105
-104
Operating Cash Flow
-16
55
-67
-86
-105
-106
-65
-98
Investing Cash Flow
36
-1
-190
-189
58
158
-51
-8
Financing Cash Flow
1
0
348
171
1
45
45
126
Change in Cash
21
54
91
-104
-46
97
-71
19

Global Institutional Holdings in C4 Therapeutics

Check out the Institutions with significant holdings in C4 Therapeutics.

Funds
Holdings
Peter Kolchinsky
6.50%
Vanguard
4.40%
iShares
4.08%
WASATCH FUNDS TRUST
3.47%
VANGUARD INDEX FUNDS
3.07%
See all

C4 Therapeutics News & Key Events

  • img

    Today's Timeline - 25 September

    Fri, 04:40 PM

    -

    C4 Therapeutics presents biomarker data from Phase 1 trial of cemsidomide, showing robust T-cell activation and safety for further trials.

Insights on C4 Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -25.12M → -23.63M (in $), with an average increase of 6.3% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 6.15M → 6.64M (in $), with an average increase of 7.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 723.8% return, outperforming this stock by 686.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 120.0% return, outperforming this stock by 80.3%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, CCCC stock has moved down by -19.0%

About C4 Therapeutics

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
OrganisationC4 Therapeutics
Headquarters490 Arsenal Way, Watertown, MA, 02472, US
IndustryBiotechnology
CEOAndrew J. Hirsch

Key Management of C4 Therapeutics

Name

Title

Mr. Roy Pollock Ph.D.

Senior Vice President of Biological Sciences

Dr. Leonard M. J. Reyno M.D.

Chief Medical Officer

Dr. Kenneth C. Anderson M.D., Ph.D.

Co-Founder, Independent Director & Member of Scientific Advisory Board

Ms. Kendra R. Adams

Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer

Dr. Nathanael S. Gray Ph.D.

Co-Founder & Member of Scientific Advisory Board

Ms. Courtney Solberg

Senior Manager of Investor Relations

Ms. Kelly A. Schick

Chief People Officer

Dr. Isabel Chiu Ph.D.

Senior Vice President of Strategic Alliances & Business Development

Dr. Christopher Nasveschuk

Senior Vice President of Chemistry

Mr. Andrew J. Hirsch M.B.A.

CEO, President & Director

FAQs

What is C4 Therapeutics share price today?

C4 Therapeutics share price today is $2.65 as on . C4 Therapeutics share today touched a day high of $2.79 and a low of $2.64.

What is the 52 week high and 52 week low for C4 Therapeutics share?

C4 Therapeutics share touched a 52 week high of $5.17 on and a 52 week low of $1.69 on . C4 Therapeutics stock price today i.e. is trending at $2.65,which is 48.74% down from its 52 week high and 56.80% up from its 52 week low.

What is C4 Therapeutics's market capitalisation today?

C4 Therapeutics market capitalisation is $0.00T as on .

How to invest in C4 Therapeutics Stock (CCCC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for C4 Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy C4 Therapeutics Stock (CCCC) from India?

Indian investors can start investing in C4 Therapeutics (CCCC) shares with as little as ₹95.13999938964844 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹951.40 in C4 Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on C4 Therapeutics share’s latest price of $2.65 as on October 14, 2026 at 10:39 pm IST, you will get 3.7736 shares of C4 Therapeutics. Learn more about fractional shares .

What are the returns that C4 Therapeutics has given to Indian investors in the last 5 years?

C4 Therapeutics stock has given -93.71% share price returns and 27.71% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?